Health and Healthcare

Pfizer : PFE

All Pfizer Articles

1491 Articles

Lee Jackson | May 25, 2016 at 10:05 AM EDT

4 UBS Most Preferred Pharmaceutical Stocks That Pay Big Dividends

Despite the ongoing political candidate chirping, all of these quality big pharmaceutical stocks have been around, and they will continue…

Chris Lange | May 25, 2016 at 8:15 AM EDT

Short Sellers Take Mixed Stance on Major Pharma

The May 13 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks short…

Trey Thoelcke | May 25, 2016 at 6:10 AM EDT

The 5 Most Shorted NYSE Stocks: Short Sellers Pick a New Favorite

However, one medical supply company stood out, as short sellers piled on Baxter International in the first two weeks of…

Chris Lange | May 19, 2016 at 10:20 AM EDT

8 Stocks on the Move After ASCO Cancer Abstracts

ASCO has just released the abstracts for its exhibitors ahead of the conference. For investors and analysts, sometimes winners or…

Paul Ausick | May 16, 2016 at 7:50 AM EDT

Pfizer Pays $5.2 Billion for Anacor

Pfizer has announced that it has reached a definitive agreement to acquire Anacor Pharmaceuticals in a deal valued at more…

Chris Lange | May 12, 2016 at 7:40 AM EDT

ASCO Could Make or Break These 7 Cancer Drug Trials

The king of biotech and pharma events is about to take place. The 2016 annual meeting of the American Society…

Chris Lange | May 11, 2016 at 8:45 AM EDT

Major Pharma Short Interest Continues to Recede

The short interest data have been released for the April 29 settlement date, and for most of the selected pharmaceutical…

Trey Thoelcke | May 11, 2016 at 6:20 AM EDT

The 5 Most Shorted NYSE Stocks: Short Sellers Still in Retreat

As the markets reached all-time highs last month, the short sellers were in retreat, judging by the moves in the…

Jon C. Ogg | May 10, 2016 at 8:55 AM EDT

Top Analyst Upgrades and Downgrades: Bats, Eli Lilly, Gap, Hasbro, JD.com, Nike, Pfizer, SolarCity and More

The top analyst upgrades, downgrades and initiations seen on Tuesday morning include Bats Global Markets, Eli Lilly, Gap, Hasbro, JD.com,…

Lee Jackson | May 9, 2016 at 10:05 AM EDT

4 Top Blue Chip Dividend Stocks to Buy and Hold Forever

These stocks should do well for years regardless of who the next president is. They all have incredible franchises, long…

Paul Ausick | May 7, 2016 at 12:30 PM EDT

Analysts Adjust Predictions on Medivation Buyout Price

One time when missing earnings estimates doesn't matter much is when there is bidding war for the company. That's the…

Trey Thoelcke | May 5, 2016 at 7:35 AM EDT

3 Big Pharma Stocks With Credible Threats to Their Blockbusters

A pharmaceutical company could face a threat to one of its products for a number of reasons, ranging from an…

Paul Ausick | May 3, 2016 at 4:01 PM EDT

The 5 Dow Stocks That Defied the Selling Tuesday

May 3, 2016: Markets opened lower Tuesday following some overnight weakness in overseas markets resulting from weak data on trade…

Paul Ausick | May 3, 2016 at 7:25 AM EDT

Pfizer Boosts Guidance With Help From Hospira, Weaker Dollar

Pfizer reported better-than-expected first-quarter 2016 results before markets opened Tuesday morning.

Chris Lange | May 2, 2016 at 12:15 PM EDT

What to Expect From Pfizer Earnings

Pfizer is scheduled to report its first-quarter financial results before the markets open on Tuesday.

1 … 49 50 51 52 53 … 100

Pfizer : PFE

All Pfizer Articles

4 UBS Most Preferred Pharmaceutical Stocks That Pay Big Dividends

Short Sellers Take Mixed Stance on Major Pharma

The 5 Most Shorted NYSE Stocks: Short Sellers Pick a New Favorite

8 Stocks on the Move After ASCO Cancer Abstracts

Pfizer Pays $5.2 Billion for Anacor

ASCO Could Make or Break These 7 Cancer Drug Trials

Major Pharma Short Interest Continues to Recede

The 5 Most Shorted NYSE Stocks: Short Sellers Still in Retreat

Top Analyst Upgrades and Downgrades: Bats, Eli Lilly, Gap, Hasbro, JD.com, Nike, Pfizer, SolarCity and More

4 Top Blue Chip Dividend Stocks to Buy and Hold Forever

Analysts Adjust Predictions on Medivation Buyout Price

3 Big Pharma Stocks With Credible Threats to Their Blockbusters

The 5 Dow Stocks That Defied the Selling Tuesday

Pfizer Boosts Guidance With Help From Hospira, Weaker Dollar

What to Expect From Pfizer Earnings

Procter & Gamble vs. Colgate-Palmolive: One Dividend Giant Stands Above the Rest

Jim Cramer: CoreWeave’s Backlog ‘May Be Much Greater’ Than Wall Street Thinks

Google, SpaceX, Microsoft, and Amazon Are About to Spend ‘Twice the Entire U.S. Defense Budget’ on AI

SECURE 2.0 Changes Force High Earners to Rethink 401(k) Strategy. Here's the Math.

The RFK Jr. Medicare AI Program Already Denying Seniors Care in 6 States

Procter & Gamble vs. Colgate-Palmolive: One Dividend Giant Stands Above the Rest

Jim Cramer: CoreWeave’s Backlog ‘May Be Much Greater’ Than Wall Street Thinks

Pfizer : PFE

All Pfizer Articles

4 UBS Most Preferred Pharmaceutical Stocks That Pay Big Dividends

Short Sellers Take Mixed Stance on Major Pharma

The 5 Most Shorted NYSE Stocks: Short Sellers Pick a New Favorite

8 Stocks on the Move After ASCO Cancer Abstracts

Pfizer Pays $5.2 Billion for Anacor

ASCO Could Make or Break These 7 Cancer Drug Trials

Major Pharma Short Interest Continues to Recede

The 5 Most Shorted NYSE Stocks: Short Sellers Still in Retreat

Top Analyst Upgrades and Downgrades: Bats, Eli Lilly, Gap, Hasbro, JD.com, Nike, Pfizer, SolarCity and More

4 Top Blue Chip Dividend Stocks to Buy and Hold Forever

Analysts Adjust Predictions on Medivation Buyout Price

3 Big Pharma Stocks With Credible Threats to Their Blockbusters

The 5 Dow Stocks That Defied the Selling Tuesday

Pfizer Boosts Guidance With Help From Hospira, Weaker Dollar

What to Expect From Pfizer Earnings

Procter & Gamble vs. Colgate-Palmolive: One Dividend Giant Stands Above the Rest

Jim Cramer: CoreWeave’s Backlog ‘May Be Much Greater’ Than Wall Street Thinks

Google, SpaceX, Microsoft, and Amazon Are About to Spend ‘Twice the Entire U.S. Defense Budget’ on AI

Featured Reads

SECURE 2.0 Changes Force High Earners to Rethink 401(k) Strategy. Here's the Math.

The RFK Jr. Medicare AI Program Already Denying Seniors Care in 6 States